# WHAT ARE THE COSTS AND BENEFITS OF AUTHORISATION: RESULTS OF THE STUDY ON THE IMPACTS OF AUTHORISATION

Stock-taking conference on the implementation of REACH authorisation

14th November 2017

Presentation by Rohit Mistry (eftec)









# **OVERVIEW**

Costs

Benefits

Summary

## **COSTS**

European Chemicals Agency


Member State Competent Authorities

3 European Commission

Third parties

5 Industry







Authorisation-

2%


## MEMBER STATE COMPETENT AUTHORITIES



## **EUROPEAN COMMISSION**



### COSTS TO THIRD PARTIES: PUBLIC CONSULTATION SUBMISSIONS



### **COSTS TO THIRD PARTIES: PUBLIC CONSULTATION**

### Public consultation on the inclusion of a substance in the Candidate List

Number of public consultation submissions received per substance:

• Median: 13

• Minimum: 1

• Mean: 18

• Maximum: 245





### Public consultation on the inclusion of an SVHC in Annex XIV

Number of public consultation submissions received per substance:

• Median: 16

• Minimum: 1

• Mean: 35

• Maximum: 493

### Time taken to produce response



### Public consultation on AfAs

Number of public consultation submissions received per substance:

Median: 11

• Minimum: 1

• Mean: 54

• Maximum: 449


### Time taken to produce response




### **INDUSTRY: COMPLIANCE COSTS**


> 71% of survey respondents (n=45/63) stated that they had incurred some form of compliance cost

Number of respondents (n=45) that incurred the following types of compliance costs:




### **INDUSTRY: COSTS OF SUBSTITUTION**







### **INDUSTRY: COSTS OF SUBSTITUTION**



## INDUSTRY: COSTS OF R&D, INNOVATION, AND INVESTMENT


> 81% (n=35 out of 43) of survey respondents indicated that authorisation has had an impact on their annual R&D, innovation, investment spending





### INDUSTRY: COSTS TO APPLY FOR AUTHORISATION

### Notional total cost - per applied for use





### Notional total costs include:

- Direct costs
- Fees
- Internal staff time

### INDUSTRY: COSTS TO APPLY FOR AUTHORISATION

### Reported mean notional total application costs per use and applicant






> Post submission costs - Mean costs to applicants in the opinion-making phase: ~€17k

### INDUSTRY: COSTS OF IMPROVED RISK MANAGEMENT

> 40% (i.e. 23 out of 57) of survey respondents indicated that they had improved risk management of SVHCs as a result of the authorisation process





# BENEFITS OF REACH AUTHORISATION

Reduction in exposure to SVHCs

Reduction in emissions of SVHCs to the environment

3 Awareness and adoption of alternatives (to SVHCs)

Benefits of substitution

5 Better information


6 Other benefits

## REDUCTION IN EXPOSURE & EMISSIONS

Improvements in RMMs where SVHCs are still be used

Substitution away from an **SVHC** 

Avoided exposure and emissions within the EU due to closing and/or relocating EU production sites



## **BENEFITS OF SUBSTITUTION - TOO EARLY TO SAY?**

**Net benefit?** 

Sales of alternative

alternative

Employment using an

77% of survey respondents who substituted identified REACH authorisation as the main driver

23% of survey respondents who substituted, attributed this to other factors

1-2

Exposure and emissions of **SVHCs** 

### BETTER INFORMATION AND COMMUNICATIONS

Use specific information on exposure and risk management

Suitability of possible alternatives

Whether society is better or worse off with continued use?

**Improved** supply chain communications

### **SUMMARY**

- Costs to EU public authorities ~€8.5 million / year
- Costs to EU applicants ~€9 million / year (based on 50 uses per year)
- Costs of substitution ~ One off costs <€1million per company (mean ~€1.5million)</p>
- Other compliance costs difficult to estimate Costs of additional RMMs associated with these applications might add another €7million / year
- Further thoughts required to mitigate/minimise some of the costs to third parties Are all submissions relevant and/or effective?
- Benefits from reductions in exposure and emissions of SVHCs Still a lack of data necessary to quantify and monetise these benefits
- Clear evidence of substitution but too early to judge the <u>net</u> impact of substitution

# CONTACT

**Rohit Mistry** 

rohit@eftec.co.uk

Tel: +44(0)207 580 5383

www.eftec.co.uk

eftec